The 10 Successful Magnetic Leaders Revamping The Healthcare

CMIC.IncLeading Treasure in Healthcare Industry
Especially in Pharmaceutical Sector
The 10 Most Successful
MAGNETIC
LEADERS
Revamping the
Healthcare 2020
MAGNETICMAGNETIC
LEADERSLEADERS
MAGNETIC
LEADERS
VOL 12 | ISSUE 01 | 2020
NETWORKING
AND BUSINESS
A CONNECTED
WORLD
GROUND REALITY
THE IMPACTS OF
PANDEMIC IN PHARMA
AND BIOTECH
LABORATORY

A Golden
Opportunity
to Win and Shine
he outbreak and the effect of Covid-19 took
Teveryone by surprise. This is a unique challenge.
We have to adapt to the “new normal” of working
remotely in our daily operations. It has forced us to
prioritize health and to focus on critical matters in both
business and life. The pandemic has its challenges and
opportunities. Although it has a lot of thought to it.
We have to see things from a positive angle and find new
opportunities in the current situation. Leaders are involved
in online leadership and scientific courses to refresh the
knowledge on the situation and connect with other
executives. Leadership styles have become contextual. A
great leader is someone who can recognize the awareness of
such a situation by interaction and adjust to the actual
reality. It is although empathy, fairness, positivity, and
leading by example that will build credibility and engage
people.
Leadership is not for everyone. If leaders decide to embark
on one such entrepreneurial venture, they should not expect
things to go according to the initial plan. They will always
face disbelievers. All you have to do is, trust your gut
feeling and channelize criticism as a motivation & driving
force, and celebrate every little win. A leader is defined as a
risk-taker. The Leader will know when it is time to abort or
cash-in, any business model. Every leader should be able to
listen, respect all points of view, make decisions for all, and
not be afraid to make those decisions. Just believe in what
you do! Stay motivated, persistent, and never give up.
Ultimately, it is important to remember that not trying is
worse than failing!
Editor’s Desk

The world of healthcare has changed exceptionally
over the last few months. Today, paramedical and
pharmaceutical leaders have become the focus of
healthcare where the aim is patient-centric. With an
intent to acknowledge and admire these passionate
leaders in healthcare, CIO Look has enlisted “The 10
Most Successful Magnetic Leaders Revamping the
Healthcare 2020” - Jenny Lin is one such healthcare
leader, COO & Board Member at CMIC, Inc. She
holds 26 years of executive/lab management
experience in bioanalytical and analytical laboratory
operations in support of drug discovery, pre-clinical,
and clinical drug development. Moreover, she is
proﬁcient in GLP, GMP, GCP, OECD, ICH, and 21
CFR part 11 regulations and business strategic
planning & execution.
Let’s unveil more alike and motivating stories of such
healthcare leaders in this special edition and spread the
word about their contribution in making this world a
better place. These leaders with their healthcare-
educational skills, business competencies, and
technical know-how, are taking healthcare to the next
level.
Finally, while ﬂipping the pages, don’t forget to go
through the articles and CXOs written by our in-house
editorial team and industry experts respectively.
Let’s begin...!
Rohit Chaturvedi

Cover Story08
CMIC Inc.
Leading Treasure in Healthcare
Industry Especially in
Pharmaceutical Sector
22
Tech Insight
Haseeb Awan
38
Article
Networking
and Business
A Connected World
26
Ground Reality
The Impacts of
Pandemic in Pharma
and Biotech Laboratory

18
Elias Chabtini
Becoming a
Trendsetter in
Cosmetic Industry
34
48
14
Elaine M. Wallace
Elevating Standards
of Education in
Healthcare
30
METRENDALYTICS
Combining Knowledge
and Technology to Bring
Efﬁciency in Business 42
Contents
Katrin Keller
A Leading Name
in the Health-Tech
Space
Karim Smaira
Committed to the
Rare Disease
Community
Triox Nano
Pioneers in point
of care programmable
medicine! presenting
the next healthcare
revolution!

sales@insightssuccess.com
December, 2020
Editor-in-Chief
Senior Sales Manager Business Development Manager
Marketing Manager
Technical Head
Technical Specialist Digital Marketing Manager
Research Analyst
Database Management Technology Consultant
Sumita Sarkar
Managing Editor
Anish Miller
Executive Editor
Rohit Chaturvedi
Assistant Editors
Jenny Fernandes
Visualizer
David King
Art & Design Director
Asha Bange
Associate Designer
Sanket Zirpe
Kshitij S Peter Collins
John Matthew
Sales Executives
David, Martin, Maneesh
Business Development Executives
Steve, Joe, Aidan, PrathameshJacob Smile
Aditya Marry D'Souza
SME-SMO Executive
Amol Wadekar Frank Adams
Circulation Manager
Robert Brown Stella Andrew David Stokes
Kushagra Gupta
Co-designer
Copyright © 2020 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any
form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success.
Reprint rights remain solely with Insights Success.
Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess
We are also available on :

Management BriefCompany Name
Karim Smaira
Founder and CEO
Metrendalytics
metrendalytics.com
Elias Chabtini
CEO
Nova Southeastern
University
nova.edu
TrioxNano
trioxnano.com
Katrin Keller
Manager
Roy Farfara
MD Founder & CTO
Elaine Wallace
Dean Professor
CMIC, Inc
cmicgroup.com
Medica Trading LLC
medicagroup.com
samedi GmbH
samedi.de
GENPHARM
genpharmservices.com
Jan Miotto
President
CMIC, Inc. was established as a strategic cornerstone for
CMIC Group’s North America growth. It has the vision to
provide a solution service as “Pharmaceutical Value Creator”
(PVC) that encompasses an entire value-chain of
pharmaceutical companies.
Genpharm is managed by senior pharma executives with vast
regional experience having held senior management roles in
multinational pharmaceutical organizations.
Medica Trading LLC is a leading Dubai-based medical trading
company, committed to providing aesthetics, dermatology, and
dental machines and products in the UAE and operating
countries which meet the expectations of the interested parties.
Metrendalytics was founded by scientists, for scientists. The
goal is to provide integrated solutions which provide a
consolidated view of all of one’s operational data—whatever
the source on one shared platform for faster interactive
collaboration and client service with reduced risk.
Elaine M. Wallace, an Osteopathic Physician, certified in
Family Medicine, Sports Medicine and Neuromusculoskeletal
Medicine.
Samedi GmbH founded in 2008 with the goal to solving
communication problems beyond the boundaries of the
individual medical practice wall and clinic wall for the benefit
of the patient.
TrioxNano’s revolutionary technology, termed S.M.A.R.T, an
acronym for Stimuli Multi Adjusted Responsive Technology, or
simply put “Programmable medicine” is based on combinations
of DNA coding, DNA molecular machines and mesoporous
nanoparticles.
Jenny Lin
Chief Operating
Officer/Board Director

Leading Treasure in Healthcare Industry
Especially in Pharmaceutical Sector
Our vision is to advance the innovation
of products and solutions that will
empower people worldwide to achieve
greater health and well-being.
Cover Story

Jenny Lin
Chief Operating Ofﬁcer
& Board Member
CMIC, Inc.

‘‘Pharmaceutical sector is blooming at
subsequently than ever being imagined.
And only few companies proved
themselves worthy of it. Meet CMIC, Inc., a
leading CRO (Contract Research Organization)
and a provider specialized in bioanalytical
services, whose cutting-edge capabilities and
sophisticated expertise in various aspects helped it
achieve a greater stature in the business. Its
bioanalytical services are in support of TK/PK/PD
Biomarker studies for pre-clinical and clinical
developments. It firmly focuses and holds
expertise in bioanalytical method development,
method validation/qualification and study sample
analysis for small, large molecules and
Oligonucleotide. The “CMIC” name originally
stood for “Current Medical Information Center”,
and the company remains committed to the
advancement of medicines and healthcare
revolution. As a strategic drug development
partner, CMIC helps sponsors to overcome
challenges in bioanalysis with expertise, rapid data
turn-around-time, and high-quality customer
services.
The company states its core values intercepted
through, W & 3C;
• WELLBEING: Fully Live Every Moment
• Challenge: Liberate opportunity by changing
our vantage point
• Change: Transform without seeking refuge in
conventional wisdom
• Communication: Proactively reach out to
people and society
The Story behind CMIC
CMIC Inc., CMIC’s Chicago, Illinois location is a
global CRO with over 30 years’ experience, the
laboratory offers bioanalysis for non-clinical and
clinical projects, both GLP and non-GLP within a
state-of-the-art facility that has the capacity to
accommodate quick turnaround for high-volume
projects. CMIC’s skilled researchers provide deep
expertise in small and large molecule bioanalysis,
biomarker services and oligonucleotide bioanalysis
expertise. Purpose built in 2010, CMIC Inc.’s
contract bioanalytical and biomarker laboratory is
located nearby Chicago O’Hare International
Airport and is one of four global contract
laboratories in the CMIC Holdings group.
Current large molecule capabilities include
detection of oligo, peptide, or antibody
therapeutics using standard ELISA or MSD-ECL
ligand-binding platforms. A variety of formats are
Our goal is to be your top tier
Bioanalysis solution
provider for drug discovery,
development through
commercialization.

available including but not limited to direct, indirect,
sandwich, competitive, and multiplex which can be
performed with off-the-shelf assays or developed in-house.
For oligonucleotide detection by hybridization, CMIC Inc.
brings a wealth of experience with capture and detection
probe-based assays for quantitation of antisense or siRNA
based therapies.
CMIC Inc.’s flow cytometer has the ability to detect up to
13 colors, and is equipped with a 96-well plate loader to
handle high-throughput applications. The software is 21
CFR Part 11 compliant, and displays easily viewed data.
Immuno-phenotyping on whole blood, PBMC, or bone
marrow can be performed with a general panel to determine
the percentage of T- and B-cells, Natural Killer, and
monocyte/macrophage lineage within the leukocyte
population. Alternatively, specialized panels such as
regulatory T-cells (Treg cells) can be characterized. Treg
cells play a role in regulating or suppressing other cells in
the immune system, and can be defined by the cellular
markers CD25, FoxP3, and CTLA4, and the intracellular
cytokines IL4 and TGFβ. Another specialized type of T-
cell (one that is important for battling foreign invaders) is
the CD4+ memory T-cell, which can be identified by
staining CD45RA and CCR7 to determine the percentage of
naïve, central memory, and effector memory T-cells within
the overall T-cell population. Other flow cytometry
applications include confirmation of gene expression in
order to establish potency of gene therapy, or the efficacy of
a treatment regimen.
Real-time qPCR has emerged as a powerful tool for
bioanalysis, and offers the ability to explore mRNA gene
expression. RNA can be isolated from whole blood,
PBMC, bone marrow, solid tissue, or matrices such as
urine, saliva, or cerebrospinal fluid and then added to a
reverse-transcriptase quantitative PCR to accurately
quantify mRNA levels. Alternatively, DNA can be isolated
and added to a qPCR to identify single nucleotide
polymorphisms, for detection of known mutations, or to
determine individual copy number variation. One of the
more powerful applications of qPCR is the ability to
multiplex, which is the detection of many targets within the
same reaction. This can be leveraged for biomarker
screening to determine which genes are differentially
regulated in response to therapeutic treatment. CMIC Inc.’s
qPCR instruments are compatible with a variety of
flourophores and are fully supported by the vendor,
providing for seamless design of specialized panels, thereby
saving precious time and cost. Yet another application for
qPCR is detection of viral nucleic acids in order to
determine the remaining levels of a vaccine or gene therapy
vector in order to establish washout and allow further
optimization of a dosing regimen.
The 10 Successful Magnetic Leaders Revamping the Healthcare, 2020
CMIC Inc. plans to add droplet digital PCR and cell-based
assays in 2021 to augment current GLP capabilities for
bioanalytical support of gene therapy programs. While
industry and regulatory contemporaries are building out a
knowledge base for new and updated assays, CMIC Inc.
will be well positioned to support large molecule biologics
ranging from monoclonal antibodies, biosimilars, anti-
cancer compounds, peptide-based therapies, gene therapy,
and vaccines.
A Glimpse into Jenny’s Life
Jenny Lin, Chief Operating Officer and Board Member.
She holds 26 years of executive/lab management
experience in bio-analytical and analytical laboratory
operations in support of drug discovery, pre-clinical and
clinical drug development. Moreover, she is proficient in
GLP, GMP, GCP, OECD, ICH and 21 CFR part 11
regulations and in business strategic planning and
execution. Her expertise includes building organizational
quality system, staff training, bioanalytical/analytical
method development/validation, bioanalytical sample
analysis, analytical development for CMC submission,
chromatography purification, stability studies, reference
standard certification, QC support for GMP manufacture.
She has been also a selected member for Global Bioanalysis
Consortium (GBC) making recommendations for global
Bioanalysis harmonization. She serves as editorial board
member for peer reviewed journal and chair for
international conferences.
Besides, she is an author and co-author for approximately
40 publications, white papers and presentations and is the
inventor of 7 issued US patents. Jenny earned her BS in
Analytical Chemistry at Peking University and her MS in
Medicinal Chemistry at University of Connecticut. She is a
member of the American Society of Mass Spectrometry
(ASMS), American Association of Pharmaceutical
Scientists (AAPS), American Chemical Society (ACS),
National Association of Professional Woman (NAPW) and
Global CRO Council (GCC).
Future of CMIC
CMIC CREED as corporate philosophy, consists of
Wellbeing, Challenge, Change and Communication
(W&3Cs). The company has been applying these
philosophy to continuously evolve itself in line with market
changes, and will do so in the future. Moreover, by further
expanding from the current “Pharmaceutical Value Creator”
(PVC) business model, the company has an aspiration to
become a “Personal Healthcare Value Creator” (PHVC) to
contribute for and to address to the up-coming personalized
medicine and individual patient quality of life.

Elaine M. WallaceElevating Standards of Education in Healthcare
The world of healthcare has changed remarkably
over the last few years. Today, the patient has
become the focus of the healthcare where the
solutions are becoming patient-centric. In its upcoming
edition “Top 10 Successful Magnetic Leaders
Revamping the Healthcare” Insights Success is praising
those leaders who are making remarkable progress in the
sector with their advanced solutions and efficient
services. One such healthcare leader is Elaine M.
Wallace, an Osteopathic Physician, certified in Family
Medicine, Sports Medicine and Neuromusculoskeletal
Medicine.
About Elaine
Elaine began her career in private practice in Kansas
City Missouri, where her practice was a true family
practice; she did her own D&C’s and tonsillectomies;
she delivered one to two babies per week; she took care
of geriatric and pediatric patients; established and was
the director of a rape crisis center at Lakeside Hospital in
Kansas City Mo. She loved family medicine, but during
the mid-80’s, she made a transition to the Kansas City
College of Osteopathic Medicine where she became the
Chair of the Department of Osteopathic Principles and
Practice. Shortly thereafter (1990), Elaine became the
Assistant Dean of Clinical Education and has spent the
remainder of her career in Medical Education.
According to Elaine, Physicians are often not educators,
so with her new role as a dean she went back to school at
University of Kansas and received a degree in Higher
Education Leadership and Administration. This has been
followed by two other master’s degrees in education
from NSU, one in Brain Based Learning as well as one
in Curriculum Development. She also has a master’s
degree in criminal justice with attention to forensic
psychology and is currently in NSU Law School in the
Education Law program.
A Proficient Educator
One of the most wonderful things about Elaine’s job is
that she oversees 6 Bachelors programs, 6 masters
programs, two PhD programs and a professional
program in Osteopathic Medicine – the largest medical
school within the state of Florida. Four of the bachelor’s
programs are “track programs” into the DO medicine
program. This means that the students take their
bachelor’s training at NSU and are offered interviews
with the DO program upon successful completion. This
has allowed the college to admit a diversity of applicants
from non-traditional fields including Public Health,
Health and Wellness Coaching, Nutrition, and soon,
Biomedical Informatics. This allows changes the
composition of a typical medical school class and fosters
a depth within the class that many other medical schools
do not enjoy.
Current Challenges and Effects
“COVID 19 offers challenges and opportunities,” says
Elaine. She further adds, the biggest challenge has been
the interruption of the third- and fourth-year clinical
rotations at affiliated hospitals, which are not able to
accommodate the students due to being overwhelmed
with COVID 19 patients. This has caused the college to
look with greater depth into online training and
simulation training. Many of these materials were
foreign, but they do offer education in a new modality
that many of the students relate to.
Learning through Reading, Travelling and
Understanding People
Elaine is an avid reader. She read one book per week.
She asserts “I have read every novel written by Joyce
Carol Oates. Having followed her career through her life
and my life, I have grown to see the nuances in people,
Top 10 Successful Magnetic Leaders Revamping the Healthcare -2020
14 | DECEMBER 2020 www.insightssuccess.com

Elaine M. Wallace,
Assistant Dean of
Clinical Education
www.insightssuccess.com 15DECEMBER 2020 |

the absurdities of life and understandings of the
vicissitudes of society.” Travelling world is also
important to Elaine. She has been in 110 countries and
on all 7 continents. She has also studied the great
religions of the world in their origin countries and has
learned that people the world over, are much the same –
wanting what is best for their families and in their lives.
Advising From Experience
Elaine opines “Every leader should be able to listen; to
respect all points of view; should demonstrate kindness;
should make decisions for all; should not be afraid to
make those decisions; should have a great sense of
humor and should not take themselves too seriously.”
On advising upcoming leaders, Elaine says “I would
recommend listening in the quiet and ﬁnding the
resonance of your passion and your mission. Then,
never sway from that.”
Combining Leadership and Team Work
Elaine believes, she is supported by wonderful teams of
people. She governs, not in a top down management, but
with two management teams, one that is administrative
with 5 members and one that is academic with 7
members. The team discusses all issues together; with
multiple people having the “30 thousand-foot view” we
are able to critique one another, guide one another and
help one another from our diverse experiences. She also
is guided by a vision of “how we get things done”, not
“can I get things done”. Elaine is not afraid, if the front
door is closed, to go through the back door or through
the window to get to where she needs to go. She also
laughs a lot. This is the key to much in life.
A Leader also A Mother
Elaine maintains a balance of personal and professional
due to the fact that she is raising three young children:
twin 8-year-old boys and a 12-year-old daughter. They
keep one’s sense of reality and reminds me every day of
the value of love and kindness over all else. She says “I
have also lived my life and my career knowing that my
values come ﬁrst and at any given moment, I could walk
away and still be a happy person.”
“Find your passion; identify your
mission; keep your eye on your
end goal; be sure you can sleep
with yourself with a clear
conscious every night; and laugh
heartily every day.”

Haseeb Awan
he days are long gone where the security threat
Tsurrounded our computer only. Modern problems
have expanded to our personal devices. The broad
classification of these threats would fall into four
categories:
1. Application-based threats;
2. Web-based threats;
3. Physical threats;
4. Network-based threats
Application-based threats: Privacy, information security,
and data security are inseparable, dependent on each other,
as well as, complimentary.
Web-application threats occur when the application
resembles an authentic application, but it is a disguise and
has the ability to skim your precious information.
The prime examples include malware and spyware where
your personal information is at stake.
Web-based threats: As subtle in nature, these web-based
threats remain unnoticed because visitors visit malicious
websites that are better from their front-end but in reality,
they are skimming your information by downloading
malicious content on your device.
Physical threats: This occurs when you lose your mobile
phone or if it has been stolen. This is a strong case for
hackers to loop into your personal information via your
device (as they have direct access to the hardware where all
your personal information is resting).
Network-based threats: This is where cybercriminals are
actively looking to encrypt your data with the use of public
Wi-Fi networks.
The advanced mobile threats comprises of:
a. Phishing attacks;
b. Data leakage;
c. Unsecure Wi-Fi (particularly public Wi-Fi) connection;
d. Sim Swap
Phishing attacks: A phishing attack is an online theft attack
that gains your personal information such as username,
password, and even your financial information. Phishing
education is mandatory to mitigate the risk of this threat to
an acceptable level. It is incumbent to learn that phishing is
different from conventional scams. The thwarting ways
would differ depending on the level of fraud committed and
who is the victim (corporation or individuals).

Tech Insight
Haseeb Awan

For corporations it would be:
1. Design policies in place and the communication should
be strong,
2. There should be a control designed to ensure the
legitimacy of an email and it should be communicated to
loyal customers (as well as others),
3. Scan the internet for likely phishing sites,
4. Implement a quality anti-virus, anti-spam, and content
filtering at the gateway.
For individuals it is simple:
1. Block malicious or fraudulent email promptly,
2. Detect and delete malicious software immediately,
3. Block the sensitive information delivery to third parties
automatically,
4. Apply skepticism wherever necessary.
Data Leakage: Data leakage occurs where there is a
compromise in the (information) confidentiality breach.
This refers to an unauthorized leakage or possible data
transmission within an organization to a third party. The lost
data is either private, sensitive, or confidential in nature.
The data could be lost due to a system crash or even a
deliberate deletion.
Ÿ Safeguards-
1. Quarantine your outgoing information (which is private,
sensitive, or either confidential in nature) from your
organization network.
2. Archive suspicious files.
3. Quarantine sensitive files to be copied into USB or
smartphones.
4. Block print jobs that contain private information.
5. Discover confidential information that is stored on
databases, organizational laptops, and workstations.
Unsecured Public Wi-Fi: Public Wi-Fi networks offer
potential privacy risks and invite security issues. People are
tempted to pursue public WiFi which is controlled by a
hacker. It invigorates the MITM attack.
Ÿ Safeguards –
1. The network should be verified. Hackers are smart but
users are smarter, it is better to play smart.
2. Using a VPN (Virtual Private Network) which is the most
secure surfing option on public networks.
3. Use Antivirus and keep the Firewall Enabled.
Sim Swap: A fraudster beautifully impersonates you and
manages to get victims Sim deactivated. There is a
replacement activation without the knowledge of the victim
(Marimuthu, V., 2019).
This is a surplus for hackers where they can reset victims'
online accounts. EFANI was designed to mitigate such
happenings with a 100% money-back guarantee for 60-
days.
Ÿ Safeguards –
1. Beware of phishing - as it penetrates sim swapping
incidents. These sketchy emails and bogus logins can get
the hacker the required information and these key data can
spawn a sim swap occurrence.
2. People should rely less on online space, they should
reduce the personal information to be stored online. Social
engineering is an initial sim swapping stage, where the
hacker collects as much information as they want. Keep
compromising information low-key such as your digits,
date of birth, mailing address off your account.
3. Protect your accounts or crypto space using Yubikey,
frequently changing the PIN, multi-factor authentication.
Please do not trust SMS-based 2FA.

A
Connected
World26 | DECEMBER 2020 www.insightssuccess.com

Networking and Business

rom speedy access to the
Finternet to the ability to
instantly get in touch with
almost anyone anywhere in the world
by dialling just a few digits, the
contemporary technology-oriented
world has changed the way we connect
and communicate. With smart devices,
people have also become smarter.
Though the processes of connecting
have become simpler, there is a need
for effective communication and
service between users, applications,
services, devices and so forth. This is
where network infrastructure comes
into the picture.
Let’s consider the current situation.
COVID-19 has compelled IT busi-
nesses to close their workplace and
made their employees work remotely.
As employees working from a different
location on enterprise networks
consists of traffic and thus, centralizing
traffic could have been a challenge for
business. To address this challenge,
there arises a need for a suitable
network infrastructure.
Along with the employee's perfor-
mance and excellent equipment, the
agility and productivity of organiza-
tions also depend on the robust and
secured network infrastructure. In
today’s digital age, businesses cannot
afford to have poor user experience and
security issues that can impact
employee productivity and thus, are
realizing the importance of adopting
comprehensive network infrastructure.
With sound networking solutions,
businesses can ensure optimum
efficiency and excellence in their
operations.
Even though enterprises have under-
stood the importance of network
infrastructure, choosing the right
networking services partner is another
challenge. Businesses are in search of
partners with integrated networking
solutions and a team that possesses the
required skill-set and industry rich
expertise. They are on the lookout for a
solution provider which they can trust
and rely on.
Taking this need into consideration,
many networking solution providers
have come forward with cutting edge
solutions and are ensuring the smooth
running of the enterprises without any
performance issue. The changes start
with migration to 5G technology. It is
built to increase the network speed and
reduce latency. It will assist in the
mobilization of employees allowing
them to work from any part of the
world.
Next up is harnessing the prowess of
Artificial Intelligence(AI) and Machine
Learning(ML) in solving business
problems in real-time. Right from
hiring the most suitable candidate to
process transformation and enriching
customer experience, AI and ML can
deliver solutions to help business
flourish.
Cloud Solutions are seen as the way
forward to maintain business continu-
ity and resilience and are being proven
effective in today’s crisis. It has helped
teams stay connected over work and
seamlessly deliver services proving
that physical distances can’t dampen
the innovative spirits. Digital experi-
ences supported by Cloud have found
new takers during the pandemic and
the technology is poised for steady
growth.
With so much dependence on net-
works, it is bound to grow complex. To
reduce and manage its complexity and
shift creation of network rules and its
maintenance, Intent-based networking
is one solution to look-out for. The idea
is to put a network control-
ler(deploying AI/ML) that can
regularly monitor the network, suggest
best paths and continuously adjust the
network performance for maximum
output.
And while we are at it, how can we not
mention Internet of Things(IoT). From
empowering manufacturing, providing
enhanced tracking to logistics, to
helping the healthcare sector in remote
monitoring and more, IoT is redefining
the way industries work and behave.
As connectivity grows, so does IoT’s
application.
Networking is evolving and with each
new step that it takes, it presents a new
opportunity for businesses to digitally
transform and scale their services.

Karim SmairaKarim Smaira
Committed to the Rare Disease Community
We strongly feel that we have a responsibility towards rare and genetic disease patients and
their families in the Middle East region,” says Karim Smaira. He is the Co-founder and
CEO of Genpharm and has worked in several geographies and served in different sales,
marketing and management functions. Karim’s entire career has been focused on international
operations and emerging markets. He left the corporate world and co-founded Genpharm in 2012. Since
then he has been serving as its CEO.
In an interview with Insights Success, Karim shares his experiences, challenges, and advises emerging
business leaders to become more resilient, motivated and focused.
Below are the highlights of the interview:
How do you diversify your organization’s healthcare offerings to entice the target audience?
We are a very focused organization with a clear vision and an aspirational purpose. We strongly feel that
we have a responsibility towards rare and genetic disease patients and their families in the Middle East
region. Access to Orphan drugs has always been complicated due to lack of overall awareness for many
of these diseases, diagnostic challenges and reimbursement issues due to the high costs of drugs in this
sector. We have built our vision on tackling these challenges through “Bringing Cures to MENA
Patients”. We diversify our offering by trying to overcome them by bringing breakthrough treatments
and innovative solutions to as many of these rare diseases as we can. We always try to walk the talk and
we are currently the first and only company that has launched gene therapy treatments in the region.
As a director and business leader, describe the challenges you are having during the pandemic
COVID-19 and what initiatives are you taking to mitigate them.
The proportion of the outbreak and the impact of Covid-19 took everyone by surprise. This is a unique
challenge. We had to adjust quickly to integrate the “new normal” of working remotely into our daily
operations. Like for many, it accelerated our adoption of digitalization. We have for example conducted
“
Top 10 Successful Magnetic Leaders Revamping the Healthcare -2020

many webinars and on-line CME conferences, reaching in fact significantly
more physicians than we would have in a physical conference, and we will
continue to do so.
We are a regional organisation with staff in many geographies. Our agility and
lean structure allowed us to adapt swiftly, to be in sync with measures taken by
different governments. We also introduced safety measures to ensure the safety
of our employees working in the office. Like with every crisis, regular
communication to and with employees in both a group and/or in individual
setting is critical and we have on many occasions as we can reassured and
engaged with them. We are very proud to be one of the few companies that
have neither reduced salaries nor let go employees; in fact we have hired 3
additional colleagues during this crisis.
What people, what books, what life factors have influenced and impacted
you?
I have been fortunate enough to cross paths with many inspiring people and
leaders throughout the years. Nevertheless, I believe the childhood years and
the civic values embedded during your upbringing, tend to guide you
throughout your life. At the risk of sounding cliché, I am convinced that traits
like honesty, respect, compassion, standing for your principles and owning your
actions, are learnt during these early
years. Your life experiences just add onto
these building blocks. I have lived in 5
different countries, learning languages
and adopting cultures along the way. This
has been one of the most determining
factors for me and has taught me the
ability to work and communicate
globally.
I am a passionate reader of geopolitics,
history, biographies, management and
leadership books. My inspiration has
come as much from visionary business
leaders, philanthropists, professional
athletes and ordinary people that have
taken inspiring initiatives. It would be
extremely difficult and unjust to list a
couple of book titles or names.
As a keynote business leader, what are
some of the vital attributes that every
leader should possess?
Leadership and leadership styles are
really contextual. A great leader is
someone who can recognise the
specificity of each situation or interaction
and adjust to the actual context. I do
believe though that empathy, fairness,
positivity and leading by example are
attributes that build credibility and
engages people.
How do you maintain balance between
your professional & personal life?
As an entrepreneur this balance is mostly
fictional, particularly in the first 3 years
of the venture. As the business is proven
sustainable as well as successful and trust
is built with employees that balance
becomes attainable. I have now become
better at making time for a family trip,
exercising regularly and satisfying some
hobbies and recently earning a boating
license.
How do you sustain your creative
leadership spirit in this crucial time?

“You never have
to apologise
for doing the
right thing.”
The current crisis has brought a lot of reflection. It forced
me to do a prioritization exercise and to focus on critical
matters in both business and life. I have enrolled in a couple
of online leadership and scientific courses to refresh some
of the knowledge and connect with other executives.
What are your future endeavours/objectives and where
do you see yourself in the near future?
My priority is to continue expanding and growing the
business both geographically and organically. We have
established ourselves as the rare disease and gene therapy
experts. We need to leverage and build on this to make sure
that patients in the Middle East are not left out of the
scientific and therapeutic benefits provided by these
innovations. We expect several breakthroughs in the near
future and we want to be positioned as the natural partner in
the region.
What advice would you like to give to the emerging
business leaders/entrepreneurs?
Entrepreneurship is not for everyone. If you decide to
embark on an entrepreneurial venture don’t expect things to
go according to your initial plan. You will always have
doubters. More people will be cheering for you to fail than
to succeed. Stick to your gut feeling and use criticism as a
motivation and a driving force. Make sure you celebrate
every little win! Nevertheless, know when it is time to pull
the plug on your idea or business model. An entrepreneur is
by definition a risk-taker. It is important to remember that
not trying is worse than failing!

The Impacts of Pandemic
in Pharma and Biotech
Laboratory
The Coronavirus disease 2019 (COVID-19) was
and is a world-changing event that has touched
the lives of everyone on the planet, but on a
positive note, it was an accelerant of technology and has
forced companies to innovate. Companies that can do it
better, faster, cheaper, more efficient, and have more
creative approaches to problem solving will leapfrog to
the forefront of the industry. We will see more of a focus
to develop and implement technology that can deliver
transparent, secure, and reliable data sharing remotely.
When COVID-19 was declared a pandemic, the industry
rapidly responded with efforts put into place to
effectively protect patient safety in their trials. Across
the world, clinical trials answering important healthcare
questions were stopped, or temporarily paused to
possibly restart later, some with important modifications.
Pharmaceutical companies and clinical research
organizations greatly felt the effects of the COVID-19
outbreak on the clinical trial life cycle and began to
incorporate remote ways of working to mitigate
disruption. Over the last decade, regulators have been
advocating for greater use of technology, virtual trials,
and SMART trial designs. In the era of COVID-19,
ongoing studies were now faced with new challenges
like site closures, quarantines and limited access to study
documents. As a result, clinical study teams are now
relying heavily on remote monitoring and a more secure
means of document sharing in order to meet clinical
study timelines.
As a laboratory solution developer for the Pharma and
Biotech industry, it's important to highlight this
background as an important framework which provides a
basis for the direct impact of the COVID-19 era on the
bioanalytical business today as well as providing insight
of what the lab of the future needs to become. For
example, direct impact for the laboratory when pharma
companies moving toward more efficient SMART
clinical trial adaptive designs, which allows for the
continual modification of the trial based on interim data,
is that in in addition to help in shortening development
time, such designs may reduce the total sample size
needed thereby reducing the number of samples that
would need to be analyzed by the laboratory. So, in a
business very much driven by the number of samples to
be analyzed, when trials are delayed or producing much
less samples, labs have to pivot more towards a focus on
other activities such as the emerging market for
biomarkers in order to fill the void from lost sample
count to analysis types that would generate the same
revenue.
In addition to evaluating different business strategies,
labs need to be able to have access to information
technology to be able to manage operations more
efficiently including managing all processes remotely. In
order to be effective, everyone needs to be well versed
and comfortable using this technology. Use of
disconnected spreadsheets or non-database sources are
Ground Reality

from home, how can we reduce the need for “essential”
lab staff to work on site? Is the lab of the future one
which places much less burden on needing so many
scientists to be on site and instead leverages integrated
operational robotics, machine learning and remote
control of these laboratory systems?
Tools that enable a flexible business model, are cost
effective, and allow for remote access will be in high
demand moving forward and will allow us to get beyond
just managing data more efficiently. This allows us the
opportunity to start doing interesting things with that
data. Technologies that facilitated the ability to do this
have been brought to the forefront in lieu of the more
typical investments of continually just adding more
people and more instruments.
As virtual and remote working prove to be sustainable
methods of laboratory operations, it is unlikely early
adopters will revert back to the more laborious and time-
consuming methods involved in the previous, high-
contact model. Consequently, companies will require
comprehensive platforms that address their changing
unmet needs and evolve their expectations of what an
integrated ecosystem can provide. Having a good
understanding of how much work is taking place
digitally will accelerate the technology enabled remote
work. At Metrendalytics, we have always recognized the
value of online work situation and had the infrastructure
in place to do so, therefore our operations did not skip a
beat during these pandemic times.
While the new normal is still unfolding, it is becoming
increasing clear that the future will be anything but
normal. We will begin to see more decentralization,
technology, and the need to make important decisions
not at the office. It is always important to remember
that during these times of disruption, uncertainty and
challenge, those who can reinvent themselves and move
forward will open a gateway to an abundance of
opportunities.
no longer a viable option
because they are
problematic for real time
sharing of information.
Despite the significant
investment that pharma has
made in technology, the #1
problem still facing the
scientist today is “Finding
data when I need it”.
Historically, technology has
focused on just replacing the
existing paper process with
electronic counterpart. We
must ask ourselves, are we
going to continue to build tools to
support existing business models and
existing ways of working or should we
begin to think about tools to reinvent the way
we do business?
Labs have now learned that they can and must work
remotely for many tasks without significant impact on
performance. Roles relating to project management
particularly fit this new paradigm very well but only if
the tools to do so are in place and folks are comfortable
with using them. The upside is improved quality of life
for staff who can significantly reduce commute time,
stress and costs. Time gained can be re-invested into
actual work for clients and conducting more science. For
the laboratory operations staff who are typically required
to be on-site as “essential” lab personnel, in addition to
adhering to typical lab safety requirements, new
pandemic related items such as spatial distancing, masks
etc have been included. Lab space available was the key
driver to ensure this was achieved. But what we have
learned is labs can actually reallocate space previously
used by project management and other remote staff and
even reduce their fixed costs on building office space etc
needed by giving folks who can work remotely the tools
and training to do so. Acting on both these learnings will
only become more important depending on how long this
pandemic lasts, and also as proactive preparedness for
the next one. Perhaps we should already be building for
this next phase? If non-essential folks can mostly work

Pharmaceutical services
consulting and software
development company,
focused on helping both
pharma and CRO's
centralize operational
data for real-time use.
‘‘ Jan Miotto
President
Metrendalytics

etrendalytics was founded by scientists, for
Mscientists. Our goal is to provide integrated
solutions which provide a consolidated view of
all of one's operational data—whatever the source—on one
shared platform for faster interactive collaboration and
client service with reduced risk.
Metrendalytics recognizes that companies need a platform
to create comprehensive efficiencies across project planning
and execution with built-in analytic tools that are easy to
implement, are highly customizable, and cost-effective. To
enable this transformation journey to optimize “running the
laboratory business” with technology requires innovative
business solutions uniquely designed and customized
around a company's specific business model and processes.
Metrendalytics works to understand and build systems to
meet the unique process needs of each company. Then we
enhance the resultant process efficiency with corresponding
operational dashboard views with automated data
integration, aggregation, and signal detection in interactive
visualizations, which allows for centralized views and
remote monitoring of project performance in real-time.
Reviewers are able to zero in on signals and trends that
could affect operational performance and make smarter
decisions sooner about how to deploy resources. This
eliminates error prone, redundant entry and information
update lag time associated with typical business
management via various spreadsheets used for tracking of
these activities which are a basis of vast inefficiencies. As a
result, companies are essentially road blocked in the ability
to unleash the power buried in their operational data.
Metrendalytics' solutions have been presented at multiple
pharma/biotech meetings and conferences over the years.
Many of these presentations were from its customers. Most
recently, it was featured in a Bioanalysis Zone article on
how Metrendalytics' remote access solutions helped
businesses continue and thrive through the Covid-19
pandemic.
Extensive Service Offerings
Metrendalytics is a Pharmaceutical consulting services and
software development company focused on helping
pharma/biotech clinical operations and CRO's laboratory
operations centralize operational data for real-time use. The
company utilizes cloud-based, scalable, modular, rapid
development, and low-cost platforms which are analytics
and visualization enabled. The key to success is its software
combines existing internal and external data into a single
platform allowing customers to gain efficiencies and make
faster, more informed decisions. As a result, the firm helps
transition a business from a process that is reactive to one
that is more proactive.
The laboratory tools and technologies in the bioanalytical
laboratory have evolved and changed. However, leveraging
real-time business data to make more informed decisions
has seen limited progress. Further, additional time is
required to manually create plots and metric reports to be
used for analytics and process improvement initiatives. As a
result, less time is available for analyzing data to improve
business outcomes, customer service, and risk reduction.
Metrendalytics' software integrates the information from
existing software like Salesforce, Watson, NetSuite, etc and
incorporates these into a suite of applications to centralize
from proposal creation, award, and management of
milestones and deliverables through QC, QA, and reporting.
This provides a “one-stop-shop” for all critical business
functions and data so that each stakeholder has what they
need to efficiently complete their part. This means
laboratory and management personnel can spend more time
doing science and serving customers instead of chasing data
and re-entering information.
Passion and Expertise
Jan Miotto, President of Metrendalytics, had a successful
career in the drug development industry because of her
ethics of hard work and wanting to make things better for
the industry. This, along with a lifelong passion to learn and
apply new technologies is what drives the success of
Metrendalytics. She has assembled a group of like-minded
successful individuals who work together with the goal of
making customers successful.
METRENDALYTICS
Combining Knowledge and Technology to Bring Efficiency in Business

Jan focuses on being authentic and bringing
value every day and trying her best not to
keep a fixed mindset in order to be able to
explore new opportunities. Jan says, “If you
wait for things to be perfect, you can miss
opportunities.” She brings a mindset to
never stop adapting. For Metrendalytics,
experimentation has helped them reach a
product-market fit.
Driving Improvement by Knowing Your
Customer
Metrendalytics' culture is to really partner
with its clients to help take them to the next
level. “We work with our customers to
understand their business, their pain points,
and where they want to be in the future,”
says Jan. Being knowledgeable in the
industry allows the company to understand
each client's specific situation and allowing
it to be flexible to design the tools they need
to be successful. The goal is to add value
and transparency to all levels of the
organization.
Metrendalytics aims to improve the “life of
the scientist in the laboratory” by providing
tools to leverage already existing
information. It helps mid-level managers
drive improvement gains through
automated capture of metrics and trends. It
also provides senior-level executives up to
the minute visibility to their entire portfolio
to understand the current status of their
projects and where action is needed to keep
programs on track. By being more efficient
with information, the company helps all
levels of the organization perform better to
help take time and cost out of the drug
development process.
Current Crisis and Future Opportunities
Metrendalytics has always been at the
forefront when it comes to how it uses the
information to improve business results. It
will continue to do so in the future. The
recent Covid-19 pandemic has accelerated
the adoption of cloud-based and remotely
accessed information systems. The
company will build on its past success in
this area to develop new and expanded

capabilities to meet the full-service needs of its customers.
The company asserts “Our low cost, rapid development
model also makes replacing some of the disconnected and
more expensive “point solution” systems possible.”
Metrendalytics continues to build a network of experienced,
results-oriented subject matter experts in the laboratory,
drug metabolism, and chemistry manufacturing and
controls. This expanded knowledge base provides access to
new markets and the opportunity to leverage its technology
to benefit these areas.
Socially Responsible
Metrendalytics is active in Corporate Social Responsibility
including philanthropy, environment conservation, diversity
and labor practices, and volunteerism. As a company,
Metrendalytics is diverse and designated as a female-
owned, minority business and some of its partners are also
minority-based.
It has donated time and resources to start-up groups and
technology companies that share the same passion for data
and using that data to build the next-generation laboratory
or improving upon existing technology to help the day-to-
day work life of the scientist.
On Drug Development Challenges
Drug development is a long and costly process typically
requiring approximately 10 years and hundreds of millions
of dollars. By developing solutions that reduce this time and
cost, Metrendalytics not only saves money for customers
but also helps get products to market faster. As a result, the
public has access to potentially life-saving medications
sooner. This in turn provides a revenue stream for the
pharma company to reinvest in future drug development.
For CROs, where the name of the game is efficiency and
value, here again, Metrendalytics helps to improve both of
these. The more efficient the resources are in a CRO, the
more projects can be completed, which accelerates drug
development as noted above. It also means better
profitability and stability for the CRO.
For both CROs and pharma biotech companies, the time
saved translates to more focus on the actual work of drug
development instead of time wasted collecting and
managing information. That time saved can then channelled
into value-added activities like quality control, assessment
and impact analysis or actions or innovations to improve
the outcome.
Testimonials from Clients
“Jan and her team at Metrendalytics collaborated with our
team at Alturas Analytics to create a total customized
information management system that organizes and
manages client information, data and resource
management. The system has improved productivity,
efficiency and compliance in our bioanalytical CRO. Thank
you Metrendalytics!”
-Shane Needham, Co-Founder and Chief Scientific
Officer at Alturas Analytics, Inc.
“Immunologix Labs is accelerating our bioanalytical
service delivery to the technology forefront with the
Metrendalytics initiative. The platform will be our primary
driver for industry-leading efficiency, organization and
client experience. It will provide the architecture to
seamlessly ensure consistent, high-quality, on-time
performance for our clients. We are very enthusiastic about
our partnership with Jahanara (Jan) Miotto and the team at
Metrendalytics"
-Michael Anderson, President and Chief Executive
Officer at Immunologix Laboratories
“We are on an exciting journey with Metrendalytics in
moving from a paper heavy lab to a paper-lite lab to a
paperless lab, which will enhance the efficiency of the
entire laboratory process, leading to a dramatic overall
cost reduction in operations and a better way to work for
everyone. Many thanks to Metrendalytics in bringing our
vision into reality”
-Luca C Matassa, VP and Head of Bioanalytical at QPS
Laboratoriese operational data for real-time use”

Triox NaPioneers in point of care programmable medicine! presenting th
n an interview with Insights Success, Triox Nano's
Imanagement describes its impeccable journey to
become the first biotech company to develop a
modular programmed drug delivery platform. The
company's revolutionary technology, termed S.M.A.R.T, an
acronym for Stimuli Multi Adjusted Responsive
Technology, or simply put “Programmable medicine” is
based on combinations of DNA coding, DNA molecular
machines and mesoporous nanoparticles. SMART offers the
potential to add programming to almost any approved
medicine that may in turn increase its efficacy
exponentially.
Prominent opinion leaders and investors had been funding
TrioxNano's development to date including the European
commission through the prestigious H2020 Horizon
program. Competing with over 1500 companies
TrioxNano's technology won a non diluting grant of
roughly $2.5 million USD. TrioxNano's all inclusive patents
are granted around the world . Many believe this
breakthrough technology may lead the way to the next
healthcare revolution!
To create S.M.A.R.T Triox Nano had to first invent the
modular hardware that will allow incorporation of many
different medications, the software language which is based
on DNA coding and the actual codes that will control the
nano particle. The technology is expected to create a
paradigm shift and highly impact human lives around
the globe, transforming medicine from its current primitive
analog state to a programmable digital modern era.
S.M.A.R.T creates a vast field of programmable
nanoparticles that can deliver their payload to target tissues
based on the software code that is uploaded to them. The
final commercialized product is expected to be supplied
with a list of common software codes. The treating
physician will decide which codes to use and will easily
upload them to the modular nanoparticle that incorporates
the relevant medication. The doctor will have the option to
upload a mixture of several codes into the same treatment
based on the patient's clinical and pathologic profile.
Under the supervision of Joseph Farfara, Triox Nano's
CEO, the company has progressed robustly in the last 3
years, broadening the type of medications that can be
loaded into the platform, improving the capping
characteristics and securing its IP with patents granted
around the world.
Below are the highlights of the interview:
Can you explain to our readers what so exciting about
Triox Nano work?
Joseph Farfara, Triox Nano's CEO “By the year 2020,
thousands of APIs (Active Pharmaceutical Ingredients) had
been developed to treat different diseases, yet not even one
efficient modular technology was developed to deliver them
accurately to their target! The most efficient way to do this
is use programming abilities so that each API can have tens
of programs to direct it to different targets upon request. If
you compare this to the car industry its like everyone has
been developing thousands of types of engines without
finding a way to connect them to the wheels yet. Current
delivery methods, such as Injections or tablets deliver only
a small percentage of their original doses to the tissues
requiring treatment, and instead, most of the dose arrives to
healthy tissue causing severe toxicity.
Examples for our programing abilities include the TXN770
family of nanoparticles intended for the treatment of TNBC
(Triple Negative Breast Cancer). TXN770 combines
between a modular unit loaded with the chemotherapy
doxorubicin, that is already approved for the treatment of
TNBC and the ability to be programmed by a combination
of different software codes that control its release according
to common traits found in the patient's specific tumor such
as high levels of Magnesium and high levels of ATP. Other
programing options we are developing include high levels

anohe next healthcare revolution!
Roy Farfara, MD
Founder & CTO
of PD1, PARP and Nucleolin found to be high in subgroups
of TNBC patients. This allows us to use the same modular
particle that includes Doxorubicin and program it to react to
different cancer traits. In parallel we have created other
modular particle loaded with the chemotherapies
Mitoxantrone and Docetaxel (that is approved already for
TNBC) that can use the same software codes described
above (Mg, ATP, PD1, PARP, Nucleolin).
We are focusing on TNBC Triple Negative Breast Cancer to
prove our technology's benefits but expect it to be relevant
for many other indications. We offer specific licenses to
the use of our S.M.A.R.T platform loaded with the
client's APIs (active pharmaceutical ingredient). This is
relevant for many types of companies, those who have a
medication that is effective but proven to be too toxic to be
used, or for medications that require high doses to be
effective, or in cases patent cliff issues have to be avoided.
Our standard license agreements includes milestone
payments and royalties fees, we offer our services for a fee
to develop the asset until completion of the of In Vitro
phase, expecting the companies to complete the In Vivo Tox
and clinical trials.
What led to the inception of Triox Nano?
Answer Dr. Roy Farfara CTO and founder of
TrioxNano
The inception of TrioxNano was at 2 AM after a long
operation of a young kidney cancer patient. Our department
was regularly accepting patients that other surgeons had
given up on operating them due to the technical difficulties.
We had the best techniques and technologies in Israel at the
time (biologic glues, mannitol, hypothermia) we were
taking out carefully tumor after tumor in the renal. We
finished the surgery exhausted though we knew we did the
best that can possibly be done. The patient kidney was not
resected, we managed to take out all tumors and substantial
bleeding avoided. Yet we understood that the patient ended

up having less than %20 of the original kidney parenchyma
meaning he would most probably need dialysis in the near
future. My grandfather Simon Farfara RIP who was an
artisan taught me when I was a child that "The first step in
every challenge is to find the best tools to complete it".
Understanding that it is not possible that in the year 2013
we are trying to resect micron (one millionths of a meter)
size cancer cells with centimeter size knifes while on the
other hand treating with chemotherapy that is not specific
enough thus causing substantial side effects. Being aware of
the limitation of surgery (trying to resect micro meter size
cancer cells with inch size knifes) and the limitations of non
specific chemotherapies causing substantial toxicity made
me understand at that moment that we are totally not using
the right tools to achieve this goal, and set me out on this
journey”
Describe Triox Nano and its cutting-edge technology.
Answer Dr. Ehud Saas head of biologic programming
Interestingly computers have been incorporated into
everyaspect of our lives except medicine. TrioxNano has
developed and patented a programmable nano delivery
platform that can carry different medications, including
chemotherapies, to their target tissue. The technology uses
nanoparticles based on DNA machinery. These amazing
machines are made from single-stranded DNA and RNA
and allow us to program a modular particle with almost
infinite possibilities. Once completed, the technology will
enable the treating physician to upload the relevant DNA
module per individual patient and precise the administered
treatment based on his specific cancer traits. It is estimated
that more than 1000 approved medication can be delivered
by this programmable system and at least 500 unique
programmed modules can be uploaded to them. This adds
up to about half a million different options of unique
treatments (in the case that only one code is uploaded per
particle), in the case a combination of three codes is loaded
and estimated 125 billion treatment options are created.
As a leading pharma and biotech solution providers, what
contribution has been made by you?
Answer by Dr. Ofer Nusbaum head of chemistry biology
interface.
TrioxNano is trying to create a paradigm shift in the way
we treat disease. Programming is urgently need to enhance
the treatment of patients. In the case of Cancer as an
example, cancer cells develop different mutations in
different organs of the same patient. On the other hand
different cancer type share common pathways. For example
the PD1 pathway is relevant for a small percentage of
TNBC patients and larger percentage in many other cancer
types, many are being treated with PD1 inhibitors. This
translate into a need for modular programmed platform that
can relate to common traits in different tumors and different
mutation in the same patient. We believe we will be able to
offer the world the first modular programmable nano
delivery platform where the physician will be able to
program the medicine he gives his patient, he will choose
from a list of software codes that we will offer commercialy
and upload it to an armantarium of medication he can
choose from. Later on we plan to offer specific
programming to less common cases that require specific
softwares. Of note is that all the different chemotherapies
are packed in the same modular nanoparticle.
Describe in brief about the work culture and the values
that drive Triox Nano.
Joseph Farfara, Triox Nano's CEO
TrioxNano is driven by a team of highly intelligent hard
working open minded scientist. All our staff have hands on
experience of years in the industry. We are roughly divided
to chemists and biologists that are integrators able to bridge
the gap between these two worlds. As an Israeli company
we try to think out the box and “cut to chase” as much as
possible basing our decision on sound science.
What are the future aspirations of Triox Nano? What
strategies are you undertaking to achieve those goals?
TrioxNano
TrioxNano aspires to be the next Microsoft and IBM, on
one hand creating "the operating system for computerized
drug delivery" and on the other developing the hardware
required to run the operation system and the code. We want
to revolutionize the way patients are treated! To achieve this
“Triox Nano’s technology offers a paradigm shift that will highly impact
human lives, transforming medicine from an analog state to an
exciting programmable digital modern era”

“It is estimated that more than 1000 approved medication can be delivered by this
programmable system and at least 500 unique programs can be uploaded to them.
This adds up to about half a million different options of unique treatments (in the
case that only one code is uploaded per particle), in the case a combination of three
codes is loaded and estimated 125 billion treatment options are created."
goal our strategies include a hybrid business model where
we develop our own drug candidate TXN770 (as a proof of
concept) for the treatment of TNBC but are actively
persuing to cooperate with others to incorporate their APIs
(Active Pharmaceutical Ingredients) into our modular
computerized platform.
How are you solving your customers' complex drug
discovery challenges?
TrioxNano
By incorporating their APIs into TrioxNano's S.M.A.R.T
platform, our partners may be able to increase eﬃcacy
while using smaller doses, creating decreased toxicity, new
IP and an exponential increase in value. This cooperation
will importantly beneﬁt humanity as thousands of
medications can be improved which translate into
improving human lifes!
What is your idea of Corporate Social Responsibility?
Joseph Farfara, Triox Nano's CEO
The hebrew saying "KOL HAMEZIL NEFESH ACHAT
KEILU HEZIL OLAM U MELO'O," meaning he who
saves one life is considered to save the world entire.
www.Smartriox.com
Joseph@TrioxNano.com

The 10 Successful Magnetic Leaders Revamping The Healthcare

The 10 Successful Magnetic Leaders Revamping The Healthcare

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (15)

Semelhante a The 10 Successful Magnetic Leaders Revamping The Healthcare

Semelhante a The 10 Successful Magnetic Leaders Revamping The Healthcare (20)

Mais de Merry D'souza

Mais de Merry D'souza (20)

Último

Último (20)

The 10 Successful Magnetic Leaders Revamping The Healthcare